Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

MoonLake Immunotherapeutics (MLTX) Operating Income (2021 - 2026)

MoonLake Immunotherapeutics' Operating Income history spans 6 years, with the latest figure at -$70.0 million for Q1 2026.

  • Quarterly Operating Income fell 47.47% to -$70.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$267.4 million through Mar 2026, down 56.58% year-over-year, with the annual reading at -$244.8 million for FY2025, 71.1% down from the prior year.
  • Operating Income came in at -$70.0 million for Q1 2026, down from -$65.2 million in the prior quarter.
  • In the past five years, Operating Income ranged from a high of -$12.9 million in Q1 2023 to a low of -$71.4 million in Q3 2025.
  • The 5-year median for Operating Income is -$19.8 million (2024), against an average of -$33.9 million.
  • The largest YoY upside for Operating Income was 68.84% in 2022 against a maximum downside of 16840.81% in 2022.
  • MoonLake Immunotherapeutics' Operating Income stood at -$16.7 million in 2022, then rose by 9.99% to -$15.0 million in 2023, then crashed by 229.9% to -$49.6 million in 2024, then tumbled by 31.54% to -$65.2 million in 2025, then decreased by 7.37% to -$70.0 million in 2026.
  • Per Business Quant, the three most recent readings for MLTX's Operating Income are -$70.0 million (Q1 2026), -$65.2 million (Q4 2025), and -$71.4 million (Q3 2025).